Kirsten K. Edmiston

Adaptive Randomization of Neratinib in Early Breast Cancer.

Michael Hogarth, Lajos Pusztai, Rita Nanda, 2016, The New England journal of medicine.

Screening for psychological and physical distress in a cancer inpatient treatment setting: a pilot study

Kirsten K. Edmiston, Kirsten K Edmiston, Drucilla Brethwaite, 2011, Psycho-oncology.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

D. Berry, L. Esserman, N. Hylton, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2020, JAMA oncology.

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2021, JAMA oncology.

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

L. Esserman, M. Troxell, D. Yee, 2018 .

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.